Perspectives on Enquiry & Evidence

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.